Kanada - englanti - Health Canada

avanstra inc - lovastatin - tablet - 20mg - lovastatin 20mg - hmg-coa reductase inhibitors

Kanada - englanti - Health Canada

avanstra inc - lovastatin - tablet - 40mg - lovastatin 40mg - hmg-coa reductase inhibitors

Kanada - englanti - Health Canada

apotex inc - nevirapine - tablet - 200mg - nevirapine 200mg - nonnucleoside reverse transcriptase inhibitors

Kanada - englanti - Health Canada

apotex inc - nevirapine - tablet (extended-release) - 400mg - nevirapine 400mg - nonnucleoside reverse transcriptase inhibitors

Yhdysvallat - englanti - NLM (National Library of Medicine)

genentech, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naprosyn, ec-naprosyn, anaprox, anaprox ds or naprosyn suspension and other treatment options before deciding to use naprosyn, ec-naprosyn, anaprox, anaprox ds or naprosyn suspension. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen as naprosyn, ec-naprosyn, anaprox, anaprox ds or naprosyn suspension is indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naprosyn suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient's weight. naproxen as naprosyn, anaprox, anaprox ds and naprosyn suspension is also indicated: - for relief of the signs and symptoms of tendonitis - for r

Yhdysvallat - englanti - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). naproxen delayed-release tablets are indicated: naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administration). naproxen delayed-release tablets are contraindicated in patients with known hypersensitivity to naproxen. naproxen delayed-release tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids.  severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings: anaphylactoid reactions and precaut

Yhdysvallat - englanti - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 375 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets usp and other treatment options before deciding to use naproxen delayed-release tablets usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen delayed-release tablets usp are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen, usp as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen delayed-release tablets usp are not recommended for initial treatment of acute pain because the absorption of naproxen, usp is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and

Yhdysvallat - englanti - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - naproxen delayed-release tablets are indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis naproxen delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see warnings and precautions ( 5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [ see warnings and precautions ( 5.7, 5.8)] - in the setting of coronary artery bypass graft (cabg) surgery [ see warnings and precautions ( 5.1)] risk summary use of nsaids, including naproxen delayed-release tablets, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including napr

Yhdysvallat - englanti - NLM (National Library of Medicine)

blenheim pharmacal, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). naproxen delayed-release tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administration). naproxen delayed-release tablets are contraindicated in patients with known hypersensitivity to naproxen. naproxen delayed

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - nevirapine anhydrous - prolonged-release tablet - 400 milligram(s) - non-nucleoside reverse transcriptase inhibitors; nevirapine